Nabriva Therapeutics plc Book Value 2011-2026 | NBRV

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Nabriva Therapeutics plc

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.29 M	53.4 M	33.1 M	41.3 M	68.6 M	82.1 M	77.3 M	109 M	-36.7 M	-23.2 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
109 M	-36.7 M	40.8 M

Quarterly Book Value Nabriva Therapeutics plc

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-4.36 M	3.29 M	25.6 M	-	44.6 M	53.4 M	63.3 M	69.2 M	55 M	33.1 M	33.1 M	33.1 M	33.1 M	41.3 M	41.3 M	41.3 M	41.3 M	68.6 M	68.6 M	68.6 M	68.6 M	82.1 M	82.1 M	82.1 M	82.1 M	77.3 M	77.3 M	77.3 M	77.3 M	109 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
109 M	-4.36 M	56.1 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Verastem VSTM	57.2 M	$ 5.04	-4.73 %	$ 349 M	USA
VistaGen Therapeutics VTGN	70.4 M	$ 0.57	-5.87 %	$ 17.6 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Adaptive Biotechnologies Corporation ADPT	225 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Xenon Pharmaceuticals XENE	755 M	$ 54.48	-1.89 %	$ 4.24 B	Canada
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Enochian Biosciences ENOB	-21.3 M	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Summit Therapeutics SMMT	659 M	$ 16.58	-3.94 %	$ 12.4 B	Britain
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 317.36	-3.29 %	$ 41.6 B	USA
Arbutus Biopharma Corporation ABUS	76.6 M	$ 4.29	-3.6 %	$ 822 M	Canada
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA
Fusion Pharmaceuticals FUSN	222 M	-	-	$ 1.41 B	Canada
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Amphastar Pharmaceuticals AMPH	789 M	$ 19.01	-2.66 %	$ 889 M	USA
Gritstone Oncology GRTS	51.8 M	-	0.42 %	$ 213 M	USA
Завод ДИОД DIOD	-243 M	-	-	-	Russia
Фармсинтез LIFE	29.8 B	-	-	-	Russia
ACADIA Pharmaceuticals ACAD	733 M	$ 20.75	-3.35 %	$ 3.44 B	USA
Aligos Therapeutics ALGS	53.5 M	$ 6.66	-5.4 %	$ 65.8 M	USA
Teligent, Inc. TLGT	5.17 B	-	-13.85 %	$ 16.1 M	USA
Viela Bio, Inc. VIE	424 M	-	-	$ 2.91 B	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Alkermes plc ALKS	1.82 B	$ 29.39	-1.77 %	$ 4.84 B	Irlanda
Cabaletta Bio CABA	112 M	$ 2.68	-4.96 %	$ 269 M	USA
AbbVie ABBV	134 B	$ 209.4	-0.81 %	$ 370 B	USA
AbCellera Biologics ABCL	967 M	$ 3.27	-2.39 %	$ 977 M	Canada
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA